The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of GFH009 in Patients With Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04588922
Recruitment Status : Recruiting
First Posted : October 19, 2020
Last Update Posted : September 1, 2023
Sponsor:
Collaborator:
Sellas Life Sciences Group
Information provided by (Responsible Party):
Genfleet Therapeutics (Shanghai) Inc.

Tracking Information
First Submitted Date  ICMJE September 28, 2020
First Posted Date  ICMJE October 19, 2020
Last Update Posted Date September 1, 2023
Actual Study Start Date  ICMJE May 10, 2021
Estimated Primary Completion Date June 30, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 29, 2023)
  • Safety and Tolerability of GFH009: Dose Limiting Toxicities (DLTs) [ Time Frame: 21 to 28 days ]
    The incidence of DLTs
  • Safety and Tolerability of GFH009: adverse events (AEs) [ Time Frame: approximately 2 years ]
    The incidence and severity of all AEs
Original Primary Outcome Measures  ICMJE
 (submitted: October 9, 2020)
  • Safety and Tolerability of GFH009: Dose Limiting Toxicities (DLTs) [ Time Frame: 21 days ]
    The incidence of DLTs
  • Safety and Tolerability of GFH009: adverse events (AEs) [ Time Frame: approximately 2 years ]
    The incidence and severity of all AEs
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 29, 2023)
  • PK parameter AUC0-t [ Time Frame: approximately 3 months ]
    Area under the plasma concentration-time curve (from zero to the time of the last measurable concentration)
  • PK parameter AUC0-∞ [ Time Frame: approximately 3 months ]
    Area under the plasma concentration-time curve (from zero to infinity)
  • Efficacy: CR [ Time Frame: 2 years ]
  • Efficacy: DOR [ Time Frame: 2 years ]
  • Efficacy: PFS [ Time Frame: 2 years ]
  • Efficacy:OS [ Time Frame: 2 years ]
  • PK parameter Cmax [ Time Frame: approximately 3 months ]
  • PK parameter Tmax [ Time Frame: approximately 3 months ]
  • PK parameter Ctrough [ Time Frame: approximately 3 months ]
  • PK parameter t½ [ Time Frame: approximately 3 months ]
Original Secondary Outcome Measures  ICMJE
 (submitted: October 9, 2020)
  • PK parameter AUC0-t (Area under the plasma concentration-time curve (from zero to the time of the last measurable concentration)) [ Time Frame: approximately 3 months ]
  • PK parameter AUC0-∞ (Area under the plasma concentration-time curve (from zero to infinity) [ Time Frame: approximately 3 months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of GFH009 in Patients With Hematologic Malignancies
Official Title  ICMJE A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies
Brief Summary GFH009 is a potent and highly selective CDK9 inhibitor. To assess the safety, tolerability, and antitumor activity of single agent GFH009, this study consists of two dose escalation groups in patients with relapsed/refractory acute myeloid leukemia (Group 1) and in patients with relapsed/refractory lymphomas (Group 2). The safety, tolerability, and antitumor activity of GFH009 in combination with venetoclax and azacitidine in patients with relapsed/refractory acute myeloid leukemia (AML) who have relapsed on or are refractory to venetoclax-based regimens will also be assessed (Group 3).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Hematologic Malignancies
Intervention  ICMJE
  • Drug: GFH009
    In the dose escalation part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the expansion part, patients will be assigned based on tumor type(s).
  • Drug: GFH009, venetoclax, azacitidine
    Group 3. Patients with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens
Study Arms  ICMJE
  • Experimental: Group 1. Dose escalation in patients with relapsed/refractory AML
    Intervention: Drug: GFH009
  • Experimental: Group 2. Dose escalation in patients with relapsed/refractory CLL/SLL or lymphoma
    Intervention: Drug: GFH009
  • Experimental: AML Patients relapsed/refractory to vene and who will be treated with GFH in combo with vene & aza
    Group 3. Patients with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens
    Intervention: Drug: GFH009, venetoclax, azacitidine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 5, 2023)		 135
Original Estimated Enrollment  ICMJE
 (submitted: October 9, 2020)		 50
Estimated Study Completion Date  ICMJE June 30, 2024
Estimated Primary Completion Date June 30, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  1. Patients with cytological or histologically confirmed relapsed or refractory hematologic malignancies (AML, CLL/SLL and lymphoma)

    • Lymphoma: At least one measurable or evaluable lesion as defined by the Lugano (2014) response criteria. Patients must have received at least 2 prior lines of systemic therapy.
    • AML (only for Group 3): Patients relapsed on or refractory to venetoclax containing regimens.

  2. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) except for patients with Gilbert's syndrome, who are included if total bilirubin is < 3 × ULN or if direct bilirubin is < 1.5 × ULN.

    • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 × ULN. For those with hepatic metastases, AST and ALT ≤ 5 × ULN.

  3. Amylase ≤1.5 × ULN
  4. Electrolytes and uric acid level need to be stable judged by investigators for at least 3 days before the first dose of GFH009 (Medical intervention is permitted).
  5. For women of childbearing potential, must consent to use highly effective methods (i.e, total abstinence, placement of an intrauterine device) of contraception during GFH009 treatment and for an additional 90 days after the last administration of study drug, if enrolled in Groups 1 or 2, and 6 months if enrolled in Group 3. Men with a partner of childbearing potential, must consent to use two highly effective methods of contraception during GFH009 treatment and for an additional 90 days after the last administration of study drug.

Exclusion Criteria

  1. Patients with bulky disease (≥ 10 cm) who require cytoreductive therapy.
  2. Symptomatic central nervous system metastases or primary lymphoma such as primary CNS lymphoma, leptomeningeal disease, or spinal cord compression. Patients with asymptomatic CNS metastases who are radiologically and neurologically stable ≥ 4 weeks following CNS-directed therapy and are on a stable or decreasing dose of corticosteroids are eligible for study entry.

  3. Severe cardiovascular disease within 6 months of study entry, including any of the following:

    • Clinically significant heart disease such as congestive heart failure requiring treatment (NYHA class III or IV), LVEF < 50% as determined by MUGA scan or echocardiogram (ECHO), (if just with historical occasional low LVEF but without any symptoms or relevant medical history, and the LVEF at screening is > 50%, the subject is eligible), or clinically significant arrythmia.
    • History/evidence of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass graft (CABG), coronary angioplasty, or stenting).
    • Average QTcF ≥ 450 msec (males) or ≥ 470 msec (females) on screening ECG.
    • Moderate or above regurgitation on echocardiogram
    • Patients with prior treatment with cardiotoxic agents who have experienced drug induced cardiotoxicities during or after treatment, where cardiotoxic agents include but are not limited to: anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone); trastuzumab and trastuzumab based ADCs; tyrosine kinase inhibitors (sunitinib, imatinib); alkylating agents (cyclophosphamide).
    • Patients with a baseline cardiac biomarker abnormality (CKMB/cTnI) will be excluded.
  4. Patients with hypereosinophilic syndrome defined as eosinophil counts in peripheral blood of ≥1,500/µ.
  5. Concurrent malignancy within 5 years (for AML patients, 2 years) prior to entry other than adequately treated cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell carcinoma, prostate cancer not requiring treatment, ductal carcinoma in situ of the breast, and superficial non-muscle invasive urothelial carcinoma (excluding T1 lesions and CIS).
  6. Active hepatitis B or hepatitis C virus infection.
  7. History of HIV infection or HIV positive at screening.
  8. Concomitant medications that are strong CYP3A4 inhibitors and strong inducers within 7 days of first dose. Avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pomelos, star citrus fruits or St. John's wort within 7 days of first dose.
  9. Medications that are known to prolong the QT interval that could not be stopped prior to study entry judged by investigator, except azole antifungal medications in AML patients.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Young Li +86 21 6882 1388 yli@genfleet.com
Contact: Clinical Trials Info at Sellas +1 646-200-5278 clinicaltrialinfo@sellaslife.com
Listed Location Countries  ICMJE China,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04588922
Other Study ID Numbers  ICMJE GFH009X2101
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Genfleet Therapeutics (Shanghai) Inc.
Original Responsible Party Zhejiang Genfleet Therapeutics Co., Ltd.
Current Study Sponsor  ICMJE Genfleet Therapeutics (Shanghai) Inc.
Original Study Sponsor  ICMJE Zhejiang Genfleet Therapeutics Co., Ltd.
Collaborators  ICMJE Sellas Life Sciences Group
Investigators  ICMJE
Study Chair: Dragan Cicic, MD SELLAS Life Sciences Group, Inc.
Study Director: Alan Zhu at GenFleet Study Chair
PRS Account Genfleet Therapeutics (Shanghai) Inc.
Verification Date June 2023

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP